Cullin-1 Promotes Cell Proliferation in Human Breast Cancer and is Related to Diabetes

Abstract

Aim

Breast carcinoma (BCA) and diabetes mellitus (DM) are two major health problems in women and the general population. Cullin-1 is reported to be an important tumor-related protein involved in cell-cycle progression, signal transduction and transcription. The aim of this work is to investigate the role of Cullin-1 in the development of BCA and to find potential relationships between Cullin-1 and diabetes in BCA patients.

Methods

To evaluate the function of Cullin-1, we entered 168 patients with primary invasive BCA in this study. Pairs of BCA tissues and adjacent noncancerous tissues from these patients were collected between 2006 and 2008. We used immunohistochemistry to analyze the correlation between Cullin-1 expression and clinicopathological variables and patient survival. In addition, we investigated the role of Cullin-1 in BCA cell proliferation.

Results

Cullin-1 expression was upregulated in BCA tissues. Enhanced immunoreactivity for Cullin-1 in BCA tissues was inversely correlated with overall survival and disease-free survival, which suggested a poor prognosis in BCA patients. Strong expression of Cullin-1 was more frequently observed in patients with estrogen receptor negativity and HER2 positivity. We also found that Cullin-1 expression was increased in BCA patients with a previous diagnosis of diabetes.

Conclusions

Our results demonstrate that increased Cullin-1 expression is significantly correlated with poor prognosis in patients with BCA. Cullin-1 might regulate BCA cell proliferation through the ubiquitin-proteasome system. Thus, Cullin-1 might be an important marker and a therapeutic target in BCA.

Keywords

Breast carcinoma Cell proliferation Cullin-1 Diabetes mellitus

Introduction

Breast carcinoma (BCA) is the leading neoplastic malignancy among women worldwide. Several BCA risk factors have been known for many years. Among these, age, a family history of BCA, early age at menarche, late age at menopause, nulliparity, late age at first birth, tall height, high body mass index, and alcohol intake are established risk factors (1). Another major health problem in industrial countries is diabetes, which shows a rising trend (2). The incidence of diabetes is higher in BCA patients at 20% compared to the general population, suggesting that blood glucose control may be important for BCA control (3). In several cohort studies it has been shown that diabetes increases both the overall and cancer-specific mortality in the general population and in BCA patients (4, 5). Evidence supporting the association between preexisting diabetes and overall mortality in BCA is extensive. However, the potential interrelations between diabetes mellitus and BCA are complicated and remain to be elucidated.

The cullin family of proteins was first identified in 1996 as being required for cell cycle exit in Caenorhabditis elegans (6) and for the G1-to-S-phase transition in budding yeast (7). Members of the cullin family (Cullin-1, Cullin-2, Cullin-3, Cullin-4A, Cullin-4B, Cullin-5, Cullin-7, PARC and APC2) provide the scaffold of Cullin-RING ubiquitin ligase (CRL) complexes responsible for a large portion of ubiquitin-proteasome system (UPS)-mediated proteolysis. The family members are characterized by an evolutionarily conserved cullin-homology domain, and serve as molecular scaffolds to facilitate the assembly of multimeric CRLs with SCF/CRL-1 as the founding member. Cullin-1 is the most extensively characterized member of the cullin family and a key component of SCF E3s, which play an indispensable role in both cell cycle progression and early embryogenesis.

This work was aimed at identifying the key molecules involved in diabetes mellitus and BCA so as to find potential targets for BCA therapy. To elucidate the function of Cullin-1, we used immunohistochemistry and analyzed the correlation between Cullin-1 expression and clinicopathological variables and patient survival. In addition, we investigated the role of Cullin-1 in BCA cell proliferation.

Materials and methods

Study Participants

A total of 168 patients with primary invasive BCA were included in the study. BCA tissues and adjacent noncancerous tissues (NCTs) were collected between 2006 and 2008 from Nanjing Hospital of Traditional Chinese Medicine, the Second Affiliated Hospital of Soochow University, and the Affiliated Hospital of Nanjing University of Chinese Medicine. Tissue samples were immediately snap-frozen in liquid nitrogen. All human materials were obtained with informed consent. The clinical information of the BCA patients is presented in Table I. The study population included 62 patients with a previous history of diabetes. Patients with a previous history of malignant tumors were excluded from the study. The Clinical Research Ethics Committee of Nanjing University approved the research protocols and written informed consent was obtained from the participants.

RNA Extraction and Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

Total RNA was extracted using the TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The concentrations were determined using a NanoDrop 1000 spectrophotometer (Thermo Scientific). cDNA was synthesized with the PrimeScript RT reagent kit (TaKaRa) using 500 ng total RNA as the template. qRT-PCR analyses were conducted to quantitate the relative mRNA expression using SYBR Premix Ex Taq (TaKaRa) with beta-actin as internal control. The results were defined from the threshold cycle (Ct), and relative expression levels were calculated by means of the 2^-∆∆Ct method (8). PCR was performed using an ABI 7900HT instrument (Applied Biosystems). The primers used for PCR analysis are listed in the supplementary material (Supplementary Table S1 - Primer sequences. Available online at www.biological-markers.com).

Immunohistochemical Staining

Tissue arrays were constructed using the 168 paired BCA tissues and NCTs. Immunohistochemical staining was performed on 4-μm sections of paraffin-embedded tissues. Cullin-1 antibody (Abgent) and estrogen receptor (ER), progesterone receptor (PR) and HER2 antibodies (Roche) were prepared. To determine the expression level of Cullin-1 protein, slides were incubated in Cullin-1 antibody diluted 1:200 at 4°C overnight. The subsequent steps were performed using the EnVision FLEX High pH visualization system (Dako) according to the manufacturer's instructions. The ER, PR and HER2 proteins were tested using the Benchmark XT (Roche) according to the manufacturer's instructions. The HER2-positive score was based on the 2013 ASCO guidelines.

Cell Culture and Cell Proliferation Assay

Two human BCA cell lines, MDA-MB-231 and BT-549, were purchased from the American Type Culture Collection. MDA-MB-231 and BT-549 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Invitrogen). HEK-293T cells were cultured in DMEM. The cells were incubated with 5% CO₂ at 37°C. Cell proliferation was quantified using the Cell Counting Kit-8 (CCK-8, Dojindo Laboratories) according to the manufacturer's instructions. Two thousand cells were planted into 96-well plates and OD450 was tested every 24 hours.

Vector Construction and Oligonucleotide Transfection

The open reading frame (ORF) of Cullin-1 was amplified by nested PCR and cloned into the pLVX-IRES-Neo vector (Clontech). The primers and endonuclease sites used for the vector constructs are shown in the supplementary material (Supplementary Table S1). Virus particles were harvested 48 hours after cotransfecting pLVX-Cullin-1 with the packaging plasmid ps-PAX2 and the envelope plasmid pMD2G into HEK-293T cells using Lipofectamine 2000 reagent (Invitrogen). MDA-MB-231 and BT-549 cells were infected with recombinant lentivirus-transducing units plus 6 μg/mL polybrene (Sigma). Small interfering RNAs (siRNAs) of Cullin-1 were synthesized (Ribobio). Oligonucleotide transfection was performed using Lipofectamine 2000 reagent according to the manufacturer's instructions. The final siRNA concentration in the transfection mixture was 50 nM.

Xenograft Tumor Model

Male BALB/c athymic nude mice at 5 weeks of age (purchased from Vital River) were bred in a licensed SPF (special pathogen-free) grade laboratory. A total of 3 × 10⁶ cells (MDA-MB-231 and BT-549, stably expressing Cullin-1 or the vector control) in 200 μL of RPMI 1640 were injected subcutaneously in the right flank of each mouse. After transplantation, the growth of the subcutaneous tumors was assessed twice a week. Tumor size was monitored by measuring the length and width with calipers, and volumes were calculated with the formula (L × W²) × 0.5, where L is the length and W the width of the tumor. The mice were sacrificed after a period of 6-7 weeks, and the weights of the subcutaneous tumors were recorded. All protocols were approved by the Nanjing University animal ethics committee.

Statistical Analyses

The results are presented as mean values ± standard errors of the mean. The association between Cullin-1 staining and the clinicopathological parameters of the BCA patients were evaluated by the χ² test. Overall survival rates were calculated actuarially according to the Kaplan-Meier method with the log-rank test and were measured from the day of surgery. Differences between groups were estimated using the χ² test, Student's t-test, the Mann-Whitney U-test, and repeated-measures ANOVA test. Relationships were explored by Spearman's correlation. P values <0.05 were considered statistically significant.

Results

Clinicopathological Features of the Patients

One hundred sixty-eight patients with primary invasive BCA were included in the study. All patients were pathologically diagnosed as having invasive ductal carcinoma. Sixty-two patients had also been diagnosed with type 2 diabetes. The clinicopathological features of the study group are summarized in Table I.

Table I

Patient information

Characteristics
Gender
Female	168
Age at diagnosis (years)
Mean ± SD	52 ± 8
Median (range)	50 (31-79)
Histological grade
1	10
2	72
3	86
Histological type
IDC	168
Tumor size (cm)
≤2	82
2-5	95
≥5	21
Lymph node status
Positive	85
Negative	83
Diagnosed diabetes
Yes	62
No	106

IDC = invasive ductal carcinoma.

Cullin-1 Expression in Human BCA Tissues

The expression level of Cullin-1 was remarkably upregulated in 110 of the 168 (65.5%) BCA tissues when compared to the corresponding NCTs by qRT-PCR (Fig. 1A, 1B). Only 17 cases (10.1%) were downregulated while 41 cases (24.4%) were unchanged. To further demonstrate Cullin-1 protein expression levels in BCAs, immunohistochemistry was performed. The Cullin-1 protein showed typical nuclear staining in BCA tissues. The cases were scored from 0 to 3 according to the percentage of positive cells (score 1: 0%-25%, score 2: 25%-50%, score 3: 51%-75%, score 4: 76%-100%) (9). The BCAs scored as 1-2 were designated as Cullin-1 low expression while those scored as 3-4 were designated as Cullin-1 high expression (Fig. 2A). Importantly, enhanced immunoreactivity of Cullin-1 in BCA tissues was inversely correlated with overall survival (OS) and disease-free survival (DFS), which suggested a poor prognosis for these BCA patients (Fig. 2B, 2C).

Fig. 1

Cullin-1 mRNA expression in BCA patients. (A) Cullin-1 mRNA expression measured by qRT-PCR was significantly upregulated in 168 paired BCA tissues compared with NCTs. GAPDH was used as internal control. (B) Cullin-1 expression was upregulated in 65.5%, downregulated in 10.1%, and unchanged in 24.4% of the BCA samples. BCA = breast carcinoma; NCTs = noncancerous tissues.

Fig. 2

Cullin-1 protein expression in BCA patients. (A) Cullin-1 protein showed typical nuclear staining in BCA tissues. The cases were scored from 0 to 3 according to the percentage of positive cells (score 1: 0%-25%; score 2: 25%-50%; score 3: 51%-75%; score 4: 76%-100%). The BCAs with scores 1-2 were designated as Cullin-1 low expression while those with scores 3-4 were designated as Cullin-1 high expression (original magnification, ×100 or ×400). (B) Enhanced immunoreactivity of Cullin-1 in BCA tissues was inversely correlated with OS and DFS. BCA = breast carcinoma; OS = overall survival; DFS = disease-free survival.

Correlation of Cullin-1 Expression and ER, PR and HER2 in BCAs

ER, PR and HER2 status are significant parameters for the classification, clinical treatment and outcome of BCA. For the purpose of defining the relationship between Cullin-1 expression and ER, PR and HER2 status, protein expression was tested and the results are summarized in Table II. High expression of Cullin-1 was more frequently observed in patients with ER negativity and HER2 positivity. No association was observed between the intensity of Cullin-1 staining and PR status.

Table II

Correlation of Cullin-1 expression with ER, PR and HER2 status

	Cullin-1 expression
	n = 168	Low	High	P value
ER
≤15%	55	17	38	0.0001
>15%	113	72	41
PR
≤15%	88	41	47	0.5367
>15%	80	42	38
HER2
0-2	120	77	43	0.0020
3	48	18	30

ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2.

Cullin-1 Promotes BCA Cell Proliferation in Vitro and in Vivo

The high expression of Cullin-1 in BCA tissues suggests it contributes to tumorigenesis. To confirm this inference, a cell proliferation assay revealed that overexpression of Cullin-1 significantly enhanced the growth rate of MDA-MB-231 and BT-549 cells (Fig. 3A, 3B). In contrast, silencing of Cullin-1 expression with siRNA significantly repressed the growth of MDA-MB-231 and BT-549 cells (Fig. 3C, 3D). To further assess the function of Cullin-1 in vivo, Cullin-1 overexpressing stable cell lines (MDA-MB-231 and BT-549) were constructed and tumor formation assays were run in a nude mouse model. Compared with the control group, overexpression of Cullin-1 was found to promote tumor growth with a remarkable increase in tumor volume and weight in nude mice (Fig. 4A, 4B).

Fig. 3

Cullin-1 promotes cell proliferation in vitro. (A) Cullin-1 overexpression promotes the proliferation of MDA-MB-231 and BT-549 cells. (B) Cullin-1 knockdown by siRNA represses the growth rate of MDA-MB-231 and BT-549 cells. The number of cells was determined using the Cell Counting Kit-8 assay (*p<0.05, **p<0.01.

Fig. 4

Cullin-1 enhances BCA cell growth in vivo. (A, B) The effect of Cullin-1 on tumor formation in a nude mouse xenograft model. Lentiviral vector- and Cullin-1-infected MDA-MB-231 and BT-549 cells were injected subcutaneously into the right flank of each nude mouse. The tumor formation rate was 4 for both cell lines. Tumor volume and weight were significantly increased in the Cullin-1 group compared with the control group

Cullin-1 Expression in BCA Patients Diagnosed with Diabetes before BCA

In patients with BCA, diabetes diagnosed prior to cancer is associated with advanced cancer stage and increased mortality (2). We therefore analyzed Cullin-1 mRNA and protein expression in tissues of patients with BCA only and patients with diabetes and BCA (D-BCA). Using qRT-PCR, we found that Cullin-1 was significantly upregulated in 62 D-BCA tissues compared with the corresponding NCTs (p<0.0001, Fig. 5A). Moreover, high expression of Cullin-1 was observed in D-BCA tissues compared with BCA tissues (Fig. 5B). Cullin-1 protein expression was also frequently increased in D-BCA tissues compared with BCA tissues (Fig. 5C, 5D).

Fig. 5

Cullin-1 expression in D-BCA patients. (A) Cullin-1 was remarkably upregulated in 62 paired D-BCA tissues compared with the corresponding NCTs by qRT-PCR. (B) High expression of Cullin-1 was observed in D-BCA tissues compared with BCA tissues. (C, D) Cullin-1 protein expression was frequently increased in D-BCA tissues compared with BCA tissues. BCA = breast carcinoma; D-BCA = breast carcinoma and diabetes; NCTs = noncancerous tissues.

Discussion

BCA is a common malignancy in women (10). In many countries and regions, it is the most common malignant tumor in women, and as a result it is one of the main causes of death in women (11, 12). Diabetes is an endocrine disease with an increasing annual incidence rate. A report has suggested that the incidence rate increases by 7% every 10 years (4). Epidemiological evidence suggests preexisting diabetes is associated with increased risk of BCA (13), advanced cancer stage at diagnosis (4, 14), altered treatment regimens (3, 15), chemotherapy toxicity (3), BCA mortality in the general population (5, 16), and overall mortality in those diagnosed with BCA (17).

The ubiquitin-proteasome system plays an important role in maintaining the balance between normal growth and uncontrolled proliferation by regulating a large variety of cellular proteins (18). The cullin family of ubiquitin ligases, including Cullin-1, 2, 3, 4A, 4B, 5 and 7, represents the largest class of E3 ligases, with Cullin-1 being the most extensively characterized family member and a key component of SCF E3s (18). This is the first study to investigate Cullin-1 in BCA and compare its expression between BCA tissues and D-BCA tissues. In this study, High expression of Cullin-1 in BCA tissues was inversely correlated with OS and DFS. Which was similar to the results reported by Bai et al (19). Furthermore, higher expression of Cullin-1 was observed in D-BCA tissues than BCA tissues, and Cullin-1 protein expression was more frequently increased in D-BCA tissues than BCA tissues.

ER, PR and HER2 status all influence the prognosis of BCA patients and the likelihood of response to systemic therapies (20). Endocrine therapy is probably the most important systemic therapy for hormone receptor-positive BCA (21). The loss of ER expression is thought to be involved in endocrine therapy resistance. In addition, Min et al (9) reported that Cullin-1 expression was correlated with histological grade, negative ER, and positive HER2, and that it showed a significant association with poor overall survival in BCA. Similarly, our study showed that high expression of Cullin-1 was more frequently observed in patients with ER negativity and HER2 positivity. No association was observed between the intensity of Cullin-1 staining and PR status.

Cullin-mediated substrate degradation involves a wide range of cellular processes such as proliferation, apoptosis and differentiation. Once the cell regulatory mechanisms of cullin encounter malfunctions or perturbations, accumulation of oncoproteins or excessive degradation of tumor suppressors will inevitably occur, which may provoke cells into malignant transformation and tumorigenesis (18). We found that Cullin-1 promotes BCA cell proliferation in vitro and in vivo.

Conclusion

Footnotes

Financial support: Youth Scientific Funding of the National Natural Science Foundation of China, grant number NSFC-81402487.

Conflict of interest: None.

References

Hankinson

Colditz

Willett

Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 2004;6(5):213–218

Schott

Schneeweiss

Sohn

Breast cancer and diabetes mellitus. Exp Clin Endocrinol Diabetes 2010;118(10):673–677

Srokowski

Fang

Hortobagyi

Giordano

Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 2009;27(13):2170–2176

Peairs

Barone

Snyder

et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011;29(1):40–46

Zhou

Qiao

Zethelius

et al; DECODE Study Group. Diabetes, prediabetes and cancer mortality. Diabetologia 2010;53(9):1867–1876

Kipreos

Lander

Wing

Hedgecock

cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family. Cell 1996;85(6):829–839

Mathias

Johnson

Winey

et al. Cdc53p acts in concert with Cdc4p and Cdc34p to control the G1-to-S-phase transition and identifies a conserved family of proteins. Mol Cell Biol 1996;16(12):6634–6643

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25(4):402–408

Min

Kim

et al. Diagnostic and prognostic relevance of Cullin1 expression in invasive ductal carcinoma of the breast. J Clin Pathol 2012;65(10):896–901

10.

Ishikawa

Shimizu

Kito

et al. Breast cancer manifested by hematologic disorders. J Thorac Dis 2012;4(6):650–654

11.

Wheeler

Kohler

Reeder-Hayes

et al. Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. J Cancer Surviv 2014;8(4):603–610

12.

Wang

Zhu

Zhao

Leung

Carbon coated superparamagnetic iron oxide nanoparticles for sentinel lymph nodes mapping. Quant Imaging Med Surg 2012;2(1):53–56

13.

Larsson

Mantzoros

Wolk

Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007;121(4):856–862

14.

Liu

Sundquist

Hemminki

The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer 2012;118(5):1353–1361

15.

Yancik

Wesley

Ries

LAG

Havlik

Edwards

Yates

Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285(7):885–892

16.

Campbell

Newton

Patel

Jacobs

Gapstur

Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012;35(9):1835–1844

17.

Patnaik

Byers

DiGuiseppi

Dabelea

Denberg

Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011;13(3):R64

18.

Lee

Zhou

Cullins and cancer. Genes Cancer 2010;1(7):690–699

19.

Bai

Zhou

Chen

et al. Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol 2011;42(3):375–383

20.

Germano

Kennedy

Rani

et al. MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int J Cancer 2012;130(9):1991–2002

21.

Bernstein

Lacey

Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative?

J Natl Cancer Inst 2011;103(6):451–453